all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 28247 | 28268 | 28199 | 0.02 % | |
| S&P500 | 3180 | 3184 | 3176 | 0 % | |
| Nasdaq 100 | 8510 | 8516 | 8491 | 0.11 % | |
| Euro Stoxx 50 | 3750 | 3752 | 3729 | 0.87 % | |
| FTSE 100 | 7296 | 7297 | 7245 | 0.24 % | |
| CAC40 | 5904 | 5919 | 5844 | 0.8 % | |
| DAX | 13371 | 13383 | 13298 | 0.85 % | |
| Hong Kong HSI | 27573 | 27583 | 27402 | 1.57 % | |
| Nikkei 225 | 24016 | 24061 | 23828 | 0.42 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 28245 | 0.01% |
|---|---|---|
| S&P500 | 3180 | -0.01% |
| Nasdaq 100 | 8510 | 0.1% |
| FTSE 100 | 7295 | 0.23% |
| CAC40 | 5904 | 0.8% |
|---|---|---|
| Nikkei 225 | 24016 | 0.42% |
| Euro Stoxx 50 | 3750 | 0.87% |
| DAX | 13370 | 0.84% |
Latest news
| HM Dunn AeroSystems Participates in White House Summit |
| Meetings Rescheduled with Independent Mediators and USW |
| Sprout Social Announces Pricing of Initial Public Offering |
| 4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ADTRAN (ADTN) Investors with Losses to Contact Its Attorneys, Application Deadline Approaching |
| Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock |
| InterDigital Board of Directors Declares Regular Quarterly Cash Dividend |
| The New Ireland Fund, Inc. Announces Suspension of Managed Distribution Policy |
| Keytronic Starts Production at its New Da Nang, Vietnam Manufacturing Facility |
| Keytronic Celebrates its 50 Year Anniversary and Announces a Major Rebranding and New Web Site |
| Entrec Corporation Signs Definitive Agreement to Sell Its Canadian Crane Business and Assets to Sterling Crane |
| Grupo Aeroportuario Del Pacifico announces Approval of Master Development Programs and Passenger Tariffs for Its Airports for 2020-2024 Period |
| Giga-tronics Incorporated Announces Completion of Previously Announced Reverse Split of Common Stock |
| CAPREIT Expands Presence in Calgary Market |
| Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 |
| Tourism Authority of Thailand joins hands with Thai private sector to organise biggest national new year countdown fireworks along river at ICONSIAM |
| OHA Investment Corporation Announces Stockholder Approval of Proposed Merger With Portman Ridge Finance Corporation |
| Clinical Data from Reprieve Cardiovascular's Successful First-in-Human Therapy for Acute Heart Failure Presented |
| Rapid Diagnostics Expert Joins Verifi H2O Advisory Board |
| OMRON and Square Enix Launch Joint Research on "AI That Helps Motivate Humans" |
| First Federal lawsuit was filed linked to the most recent Romaine lettuce E. coli outbreak |
HM Dunn AeroSystems Participates in White House Summit
WICHITA, Kan., Dec. 12, 2019 (GLOBE NEWSWIRE) -- HM Dunn AeroSystems, Inc., a US based global supplier to the aerospace and defense industry today, announced the companyâs Human Resource leader, Mona Martin, participated in The White House Summit on Child Care and Paid Leave.
Phil Anderson, the companyâs President and CEO, said, âThe ability to attract and retain team members on alternative shifts is a continuing challenge for employers across industries and sectors. Families and those in need of childcare frequently struggle to find quality, affordable care that fits their schedules. Monaâs cross industry experience and expertise in healthcare, retail, and manufacturing gives her the ability to inform and provide perspective to the Administrationâs efforts on an important issue. We are honored to have a member of HM Dunnâs senior leadership team be part of the discussion with policy advisors who are working to find ways to better support American working families.â
Earlier this year Ms. Martin supported local panel discussions and a regional senior leadership roundtable on affordable childcare hosted by Ivanka Trump, Advisor to the President, and included Health and Human Services Secretary Alex Azar, Missouri Gov. Mike Parson, and Sen. Roy Blunt of Missouri.
The Department of Health and Human Services broader efforts included other regional roundtables. As part of the senior leadership panels at each roundtable, Ivanka Trump and Secretary Azar heard from representatives of childcare providers, employers, and government agencies as well as parents. As part of todayâs White House summit meeting, Ms. Trump will present a report of her observations from those regional meetings. Ivanka Trump is hopeful that this summit will be a catalyst for future legislation.
About HM Dunn AeroSystems, Inc.
H.M. Dunn AeroSystems, Inc., a KKR portfolio company, is a manufacturer of complex aerospace components and assemblies with operations in Kansas, Texas, and Oklahoma. The companyâs capabilities include high-speed CNC machining, bonding, chemical milling, and finishing. The company specializes in small, medium and large-scale aircraft assemblies of varying complexity for the commercial aerospace and defense industry.
Meetings Rescheduled with Independent Mediators and USW
VANCOUVER, British Columbia, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (âWesternâ or the âCompanyâ) announced today that independent mediators Vince Ready and Amanda Rogers today informed the Company and the United Steelworkers Local 1-1937 (âUSWâ) that due to personal circumstances, meetings between the parties will resume next week. The parties have agreed to a media blackout during this mediation process.
The strike, which commenced on July 1, 2019, affects all the Companyâs USW certified manufacturing and timberlands operations in British Columbia, impacting approximately 1,500 of the Companyâs hourly employees and approximately 1,500 employees working for the Companyâs timberland operations and contractors.
About Western Forest Products Inc.
Western is an integrated forest products company building a margin-focused log and lumber business to compete successfully in global softwood markets. With operations and employees located primarily on the coast of British Columbia and Washington State, Western is a premier supplier of high-value, specialty forest products to worldwide markets. Western has a lumber capacity in excess of 1.1 billion board feet from eight sawmills and four remanufacturing facilities. The Company sources timber from its private lands, long-term licenses, First Nations arrangements, and market purchases. Western supplements its production through a wholesale program providing customers with a comprehensive range of specialty products.
Forward-looking Statements
This press release contains statements that may constitute forward-looking statements under the applicable securities laws. Readers are cautioned against placing undue reliance on forward-looking statements. All statements herein, other than statements of historical fact, may be forward-looking statements and can be identified by the use of words such as âwillâ, âmayâ, âexpectâ, âwouldâ and similar references to future periods. Although such statements reflect managementâs current reasonable beliefs, expectations and assumptions, there can be no assurance that forward-looking statements are accurate, and actual performance or outcomes may materially vary. Many factors could cause our actual results or performance to be materially different, including strike activity, the inability to predict the outcomes of any such activity, the inability to predict the outcome of mediation or arbitration, the timing it may take to resolve a labour dispute, a change in the Companyâs financial situation, general economic conditions, and other factors referenced under the âRisks and Uncertaintiesâ section of our MD&A in our 2018 Annual Report dated February 12, 2019.
For further information, please contact:
Media Inquiries:
Susan Dolinski
Vice President, Corporate Affairs (604) 648-4556
Investor Inquiries:
Stephen Williams
Executive Vice President & Chief Financial Officer (604) 648-4500
Sprout Social Announces Pricing of Initial Public Offering
CHICAGO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (âSprout Socialâ or the âCompanyâ) announced today the pricing of its initial public offering of 8,823,530 shares of Class A common stock at a price to the public of $17.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Capital Market on December 13, 2019 under the ticker symbol âSPT.â The offering is expected to close on December 17, 2019, subject to the satisfaction of customary closing conditions.
Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are serving as lead book-running managers for the offering. KeyBanc Capital Markets and William Blair are also acting as book-running managers. Canaccord Genuity and Stifel are acting as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from any of the following sources:
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; and
- Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on December 12, 2019. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sprout Social
Sprout Social offers deep social media listening and analytics, social management, customer care, and advocacy solutions to more than 23,000 brands and agencies worldwide. Sproutâs suite of solutions supports every aspect of a cohesive social program and enables organizations of all sizes to extend their reach, amplify their brand and create the kind of real connection with their consumers that drives their businesses forward. Headquartered in Chicago, Sprout operates across major social media networks, including Twitter, Facebook, Pinterest, Instagram and LinkedIn.
| Contact Media: Kristin Johnson Email: kristin@sproutsocial.com Phone: (312) 281-2073 Investors: Greg McDowell ICR, LLC Email: investors@sproutsocial.com Phone: (312) 528-9166 |
4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ADTRAN (ADTN) Investors with Losses to Contact Its Attorneys, Application Deadline Approaching
SAN FRANCISCO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges ADTRAN, Inc. (NASDAQ: ADTN) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover compensable damages. The December 16, 2019 lead plaintiff deadline in a securities fraud class action pending against the company is fast approaching.
Class Period: Feb. 28, 2019 - Oct. 9, 2019
Lead Plaintiff Deadline: Dec. 16, 2019
Sign Up Now: https://www.hbsslaw.com/investor-fraud/ADTN
Contact An Attorney Now: ADTN@hbsslaw.com
                      844-916-0895
ADTRAN (ADTN) Securities Class Action:
According to the complaint, throughout the Class Period, Defendants misrepresented and concealed: (1) that there were material weaknesses in the Companyâs internal control over financial reporting; (2) that, as a result, certain excess and obsolete inventory (âE&Oâ) reserves had been improperly reported; (3) that, as a result, the Companyâs financial results for certain periods were misstated; (4) that there would be a pause in shipments to the Companyâs Latin American customer; and (5) that, as a result of the foregoing, Defendantsâ positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
The Complaint alleges that on July 17, 2019, the Company announced âpreliminaryâ earnings for second quarter 2019 due to its ongoing assessment of the reasonableness of its current and previously reported E&O reserves. On this news, the Companyâs share price fell $3.69 per share, over 23%, to close at $12.13 per share on July 18, 2019, thereby injuring investors.
âWeâre focused on investorsâ losses and whether ADTRAN and senior executives intentionally misled investors by failing to timely write off unsalable inventory,â said Hagens Berman partner Reed Kathrein.
If you purchased shares of ADTN and suffered significant losses, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding ADTRAN should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ADTN@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 844-916-0895
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock
WARREN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq:AQST) (âAquestiveâ), a specialty pharmaceutical company focused on developing and commercializing differentiated products to meet patientsâ unmet needs and solve therapeutic problems, today announced the pricing of its public offering of 7,000,000 shares of common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $35.0 million. All of the shares in the offering are being offered by Aquestive. In addition, Aquestive granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about on December 17, 2019, subject to the satisfaction of customary closing conditions.
BMO Capital Markets is acting as lead book-running manager for this offering and RBC Capital Markets is also acting as a book-running manager. Wedbush PacGrow is acting as lead manager for this offering and Brookline Capital Markets, a division of Arcadia Securities, LLC, and H.C. Wainwright & Co. are acting as co-managers for this offering.
Aquestive intends to use the net proceeds of this offering for the continuation of the commercial launch of Sympazan®, preparations to support the expected launch of its product candidate, Libervantâ¢, in late 2020 (if approved by the U.S. Food and Drug Administration (the âFDAâ)), continued development of AQST-108 and other product candidates, working capital and general corporate purposes.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the âSECâ) and declared effective by the SEC on September 17, 2019. The offering of the shares of common stock is being made only by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and will be available on the SECâs website at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com; or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281, Attention: Equity Syndicate Department, by telephone at (877) 822-4089, or by E-mail at equityprospectus@rbccm.com.
This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.Â
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively-administered standard of care therapies. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.
PharmFilm®, Sympazan® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.  Aquestive has received conditional acceptance of the use of the trade name Libervant, which is subject to final FDA review and acceptance.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as âbelieve,â "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the completion and use of proceeds of the offering, statements regarding plans, objectives and anticipated timing for regulatory approval of Libervant and other product candidates; and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with uncertainties related to market conditions and the satisfaction of closing conditions related to the offering and other risks and uncertainties affecting the Company, including those described in the "Risk Factors" section and in other sections included in the preliminary prospectus supplement filed with the SEC on December 10, 2019, including the documents incorporated by reference therein, the Company's Annual Report on Form 10âKÂ filed on March 14, 2019 and its quarterly reports on Form 10-Q filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
Â
InterDigital Board of Directors Declares Regular Quarterly Cash Dividend
WILMINGTON, Del., Dec. 12, 2019 (GLOBE NEWSWIRE) -- InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.35 per share on its common stock, payable on January 22, 2020 to shareholders of record at the close of business on January 8, 2020.
About InterDigital®
InterDigital develops mobile and video technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry's most critical and complex technical challenges, inventing solutions for more efficient broadband networks, better video delivery, and richer multimedia experiences years ahead of market deployment. InterDigital has licenses and strategic relationships with many of the world's leading technology companies. Founded in 1972, InterDigital is listed on NASDAQ and is included in the S&P MidCap 400® index.
InterDigital is a registered trademark of InterDigital, Inc.
For more information, visit: www.interdigital.com.
| InterDigital Contact: Patrick Van de Wille Email: patrick.vandewille@interdigital.com +1 (858) 210-4814 | Â |
The New Ireland Fund, Inc. Announces Suspension of Managed Distribution Policy
BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- The New Ireland Fund, Inc. (NYSE: IRL) (the âFundâ), a closed-end fund, today announced that its Board of Directors (the âBoardâ) determined that it is in the best interest of the Fund and its stockholders to suspend the Fundâs managed distribution policy (the âPolicyâ). The suspension of the Policy does not impact the Fundâs investment objective of long-term capital appreciation through investment primarily in equity securities of Irish companies. The Fund will distribute to shareholders, at least annually, substantially all of its net income from dividends and interest payments and expects to distribute substantially all of its net realized capital gains annually.Â
During the regular review of the Policy by the Board, among other things, the Board considered the Policyâs potential to increase liquidity for common stockholders, and the potential such distributions would have, if any, on narrowing the discount to net asset value (âNAVâ) at which the Fundâs shares trade. The Board remains committed to its oversight of the discount and intends to continue the Fundâs share repurchase program. Â
Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fundâs investment return and principal value will fluctuate so that an investorâs shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fundâs portfolio. There is no assurance that a fund will achieve its investment objective. Past performance does not guarantee future results.
The Fund is managed by KBI Global Investors (North America) Ltd. (âKBIGIâ), a wholly owned subsidiary of KBI Global Investors Ltd. (based in Dublin, Ireland). KBI Global Investors Ltd. is majority owned by Amundi Asset Management, Europeâs largest asset manager by assets under management. KBI Global Investors Ltd. is regulated by the Central Bank of Ireland and subject to limited regulation by the Financial Conduct Authority in the UK. Details about the extent of our regulation by the Financial Conduct Authority are available from KBI Global Investors Ltd. on request. KBIGI is registered as an investment adviser with the Securities and Exchange Commission and regulated by the Central Bank of Ireland.
The Fund is listed on the New York Stock Exchange under the ticker symbol - IRL. For further information, please contact the Fund at (800) 468-6475 or investor.query@newirelandfund.com.
Website: https://newirelandfund.com
Keytronic Starts Production at its New Da Nang, Vietnam Manufacturing Facility
SPOKANE VALLEY, Wash., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Keytronic Corporation (Nasdaq KTCC), a world class provider of engineering design and electromechanical manufacturing services, today announced it has started shipping product from its new Da Nang, Vietnam manufacturing facility.
Keytronicâs Da Nang, Vietnam manufacturing facility is 133K square feet and currently has one SMT line and several final assembly lines. There is ample room to expand to 3 SMT lines and add multiple final assemble lines without any further construction. Keytronic completed this project within 8 months following site selection.
âIâm very proud of everyone who has been involved in getting our Da Nang facility up and running in such a short period of time,â said Craig Gates, President and CEO of Keytronic. âOur strategic decision to expand to Vietnam was initially fueled by the US-China trade war. However, we have received tremendous interest in the Vietnam facility both from customerâs who do have China tariff issues, and also from those that do not.â
About Keytronic
Keytronic is a leading contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico, China and Vietnam. Keytronic provides its customers full engineering services, materials management, worldwide manufacturing facilities, assembly services, in-house testing, and worldwide distribution. Its customers include some of the worldâs leading original equipment manufacturers. For more information about Keytronic visit: www.keytronic.com.
Safe Harbour Statement
Some of the statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including Keytronicâs growth opportunities, including potential success and related revenues. Forward-looking statements include all passages containing verbs such as aims, anticipates, believes, estimates, expects, hopes, intends, plans, predicts, projects or targets or nouns corresponding to such verbs. Forward-looking statements also include other passages that are primarily relevant to expected future events or revenue or that can only be fully evaluated by events that will occur in the future. There are many factors, risks and uncertainties that could cause actual results to differ materially from those predicted or projected in forward-looking statements, such as the success and timing of ramping, availability and timing and receipt of critical parts or components, as well as other risks and uncertainties detailed from time to time in the Keytronicâs SEC filings, including its most recent annual report and subsequent quarterly reports.
| CONTACTS: | Brett Larsen | Michael Newman |
| Â | Chief Financial Officer | Investor Relations |
| Â | Key Tronic Corporation | StreetConnect |
| Â | (509) 927-5500 | (206) 729-3625 |
Keytronic Celebrates its 50 Year Anniversary and Announces a Major Rebranding and New Web Site
SPOKANE VALLEY, Wash., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Keytronic Corporation (Nasdaq KTCC), a world class provider of engineering design and electromechanical manufacturing services, today announced a major new rebranding effort in conjunction with its 50th anniversary celebration.
Starting in 1969 as a keyboard manufacturer, Keytronic has sustained extensive growth over the years and an unbroken string of operationally profitable quarters for the last 15 years. What started out as a successful original equipment manufacturer (OEM) of keyboards has transitioned into one of the most successful design and manufacturing service providers in the industry.
âOver the past 50 years our logo has evolved as we have transitioned the company from a keyboard manufacturer to a full service engineering design and electromechanical manufacturing services provider,â said Craig Gates, President and CEO of Key Tronic. âOur new logo and web site reflects the youth and vitality of the many dedicated people who have worked at Keytronic over the years. We are looking forward to the next 50 years.â
About Keytronic
Keytronic is a leading contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico, China and Vietnam. Keytronic provides its customers full engineering services, materials management, worldwide manufacturing facilities, assembly services, in-house testing, and worldwide distribution. Its customers include some of the worldâs leading original equipment manufacturers. For more information about Keytronic visit: www.keytronic.com.
Safe Harbour Statement
Some of the statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including Keytronicâs growth opportunities, including potential success and related revenues. Forward-looking statements include all passages containing verbs such as aims, anticipates, believes, estimates, expects, hopes, intends, plans, predicts, projects or targets or nouns corresponding to such verbs. Forward-looking statements also include other passages that are primarily relevant to expected future events or revenue or that can only be fully evaluated by events that will occur in the future. There are many factors, risks and uncertainties that could cause actual results to differ materially from those predicted or projected in forward-looking statements, such as the success and timing of ramping, availability and timing and receipt of critical parts or components, as well as other risks and uncertainties detailed from time to time in the Keytronicâs SEC filings, including its most recent annual report and subsequent quarterly reports.
| CONTACTS: | Brett Larsen | Michael Newman |
| Â | Chief Financial Officer | Investor Relations |
| Â | Key Tronic Corporation | StreetConnect |
| Â | (509) 927-5500 | (206) 729-3625 |
Entrec Corporation Signs Definitive Agreement to Sell Its Canadian Crane Business and Assets to Sterling Crane
ACHESON, Alberta, Dec. 12, 2019 (GLOBE NEWSWIRE) -- ENTREC Corporation (âENTRECâ or the âCompanyâ), a heavy haul transportation and crane solutions provider, today announced that it has signed a definitive agreement to sell its Canadian crane business and assets to Sterling Crane, part of Marmon Crane Services, a Berkshire Hathaway company.
âThis sale is a nice strategic move for ENTREC,â commented John M. Stevens, ENTRECâs President and CEO. âThrough this sale, we will be able to significantly reduce our long-term debt. In addition, we intend to partner with Sterling Crane to be a preferred supplier of heavy haul transportation services to Sterling Crane in Canada and utilize Sterling Crane as a preferred supplier of cranes services to ENTREC in the future for our Canadian operations.â
The aggregate consideration to be paid at closing consists of cash of $21.2 million less certain holdback amounts. ENTREC will use the net proceeds from the sale to reduce its long-term debt. The asset sale is expected to close in early January 2020.
Post-sale, ENTRECâs operations will be focused on the following businesses in 2020:
- Continuing to provide a full spectrum of crane and heavy haul transportation services in the United States through its locations in North Dakota, Colorado, Texas and Wyoming. This includes ENTRECâs recent expansion into Williston, North Dakota in November 2019;
 - Providing oilfield transportation and picker truck services throughout Alberta and North-east British Columbia through its investment in ENT Oilfield Group Ltd. and Capstan Hauling Ltd; and
 - Providing specialized heavy haul transportation services throughout Western Canada.
About ENTREC
ENTREC is a heavy haul transportation and crane solutions provider to the oil and natural gas, construction, petrochemical, mining and power generation industries. ENTREC is listed on the TSX under the symbol ENT.
About Sterling Crane
Based in Edmonton, Alberta, Sterling Crane has served the Canadian energy, natural resource, construction, and industrial markets since 1954. It is part of Marmon Crane Services, whose fleet of more than 1,200 mobile cranes is among the worldâs largest.
Forward-looking Statements
This press release contains forward-looking statements which reflect ENTRECâs current beliefs and are based on information currently available to ENTREC. These statements require ENTREC to make assumptions it believes are reasonable and are subject to inherent risks and uncertainties. Actual results and developments may differ materially from the results and developments discussed in the forward-looking statements as certain of these risks and uncertainties are beyond ENTREC's control.Â
Examples of such forward-looking statements in this press release relate to, but are not limited to, (i) ENTREC's expectation that the sale to Sterling Crane will be completed and the terms on which it will be completed; and (ii) ENTRECâs intention to partner with Sterling Crane to be a preferred supplier of heavy haul transportation services to Sterling Crane and utilizing Sterling Crane as a preferred supplier of crane services to ENTREC.
Although ENTREC believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because ENTREC can give no assurance that they will prove to be correct. ENTREC may not be able to complete all required conditions to close the sale of its Canadian crane business and assets. Further, ENTRECâs ability to become a preferred supplier of heavy haul transportation services to Sterling Crane remains subject to finalization of the terms and conditions of any such arrangement.
Readers are cautioned not to place undue reliance on these forward-looking statements, which are given as of the date hereof, and to not use such forward-looking statements for anything other than their intended purpose. ENTREC undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, please contact:Â
John M. Stevens - President & CEO
Telephone: (780) 960-5625
Jason Vandenberg â CFO
Telephone: (780) 960-5630
Grupo Aeroportuario Del Pacifico announces Approval of Master Development Programs and Passenger Tariffs for Its Airports for 2020-2024 Period
GUADALAJARA, Mexico, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacifico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (âthe Companyâ or âGAPâ) announced that it has received approvals for its Master Development Programs and Passenger Tariffs for its airports in Mexico and Jamaica. The approvals were granted by the Ministry of Communications and Transportation (SecretarÃa de Comunicaciones y Transportes) in Mexico, as well as the Jamaica Civil Aviation Authority (JCAA), respectively, for the 2020-2024 period.
In Mexico, the maximum tariffs per work load unit for each airport were determined by the Federal Civil Aviation Agency (Agencia Federal de Aviación Civil âAFACâ), based on projections for traffic, operating costs and capital investments included in the Master Development Program, in accordance with the parameters established in the concession agreements.
The applicable maximum tariffs per work load unit for each airport were the following:
| TARIFAS | Â | Â | Â | Â | Â |
| Airport | 2020 | 2021 | 2022 | 2023 | 2024 |
| Guadalajara | 196.00 | 194.63 | 193.27 | 191.92 | 190.58 |
| Tijuana | 161.17 | 160.04 | 158.92 | 157.81 | 156.71 |
| Los Cabos | 284.25 | 282.26 | 280.28 | 278.32 | 276.37 |
| Puerto Vallarta | 279.61 | 277.65 | 275.71 | 273.78 | 271.86 |
| Guanajuato | 220.80 | 219.25 | 217.72 | 216.20 | 214.69 |
| Hermosillo | 169.11 | 167.93 | 166.75 | 165.58 | 164.42 |
| Mexicali | 161.62 | 160.49 | 159.37 | 158.25 | 157.14 |
| La Paz | 186.05 | 184.75 | 183.46 | 182.18 | 180.90 |
| Morelia | 258.64 | 256.83 | 255.03 | 253.24 | 251.47 |
| Aguascalientes | 174.90 | 173.68 | 172.46 | 171.25 | 170.05 |
| Los Mochis | 192.07 | 190.73 | 189.39 | 188.06 | 186.74 |
| Manzanillo | 231.12 | 229.50 | 227.89 | 226.29 | 224.71 |
The tariffs were adjusted by an annual efficiency factor of 0.7% and are expressed in Mexican pesos as of December 31, 2017, as such they will be updated per the National Producer Price Index (NPPI), excluding petroleum.
Committed investments, in accordance with the Master Development Programs approved by the authorities, are expressed in thousands of pesos with acquisition power as of December 31, 2017. As such, these will be updated per the National Producer Price Index (NPPI), construction sector, upon execution:
| Airport | 2020 | 2021 | 2022 | 2023 | 2024 | TOTAL |
| Guadalajara | 2,309,223 | 2,083,147 | 2,627,989 | 2,125,263 | 779,138 | 9,924,760 |
| Tijuana | 1,043,430 | 1,016,012 | 943,917 | 108,652 | 42,104 | 3,154,115 |
| Los Cabos | 991,503 | 781,576 | 519,091 | 127,043 | 63,723 | 2,482,938 |
| Puerto Vallarta | 1,200,632 | 1,294,890 | 761,673 | 98,598 | 35,586 | 3,391,378 |
| Guanajuato | 275,191 | 157,485 | 63,683 | 25,391 | 24,810 | 546,560 |
| Hermosillo | 137,061 | 142,313 | 69,659 | 37,426 | 32,587 | 419,046 |
| Mexicali | 110,693 | 76,465 | 104,186 | 30,923 | 16,727 | 338,994 |
| La Paz | 171,756 | 98,199 | 66,582 | 28,591 | 9,135 | 374,263 |
| Morelia | 128,757 | 98,011 | 27,673 | 20,231 | 8,468 | 283,140 |
| Aguascalientes | 136,289 | 104,915 | 97,645 | 19,090 | 21,469 | 379,407 |
| Los Mochis | 112,637 | 68,768 | 25,846 | 10,555 | 9,295 | 227,101 |
| Manzanillo | 122,220 | 73,522 | 88,242 | 18,261 | 7,757 | 310,003 |
| TOTAL | 6,739,392 | 5,995,303 | 5,396,186 | 2,650,026 | 1,050,798 | 21,831,704 |
The investment amounts are updated as of November 30, 2019, per the National Producer Price Index, construction sector, as outlined in the following table:
| Airport | 2020 | 2021 | 2022 | 2023 | 2024 | TOTAL |
| Guadalajara | 2,550,804 | 2,301,078 | 2,902,919 | 2,347,600 | 860,648 | 10,963,049 |
| Tijuana | 1,152,590 | 1,122,303 | 1,042,666 | 120,018 | 46,509 | 3,484,086 |
| Los Cabos | 1,095,230 | 863,342 | 573,397 | 140,334 | 70,390 | 2,742,693 |
| Puerto Vallarta | 1,326,237 | 1,430,356 | 841,356 | 108,913 | 39,308 | 3,746,171 |
| Guanajuato | 303,980 | 173,961 | 70,345 | 28,048 | 27,405 | 603,739 |
| Hermosillo | 151,400 | 157,201 | 76,946 | 41,341 | 35,996 | 462,885 |
| Mexicali | 122,274 | 84,465 | 115,085 | 34,158 | 18,477 | 374,459 |
| La Paz | 189,725 | 108,472 | 73,548 | 31,582 | 10,091 | 413,417 |
| Morelia | 142,227 | 108,264 | 30,568 | 22,347 | 9,354 | 312,760 |
| Aguascalientes | 150,547 | 115,891 | 107,860 | 21,087 | 23,714 | 419,099 |
| Los Mochis | 124,420 | 75,962 | 28,550 | 11,660 | 10,268 | 250,859 |
| Manzanillo | 135,006 | 81,214 | 97,473 | 20,172 | 8,569 | 342,434 |
| TOTAL | 7,444,440 | 6,622,508 | 5,960,713 | 2,927,261 | 1,160,728 | 24,115,650 |
In Jamaica, the maximum tariffs per passenger were determined by the Jamaica Civil Aviation Authority, based on projections for traffic, operating costs, the regulated assets base and committed investments as included in the Master Investment Program. Maximum tariffs are expressed in U.S. dollars and will be applicable to the corresponding year, per the following table:
| Airport | 2020 | 2021 | 2022 | 2023 | 2024 |
| Montego Bay | 15.71 | 15.89 | 16.09 | 16.28 | 16.47 |
| Kingston | 22.47 | 24.06 | 25.72 | 27.51 | 29.41 |
Investments approved by the authorities and committed in the Master Investment Program are expressed in millions of U.S. dollars and are as follows:
| Airport | 2020 | 2021 | 2022 | 2023 | 2024 | TOTAL |
| Montego Bay | 41.9 | 34.0 | 21.9 | 13.0 | 0.9 | 111.7 |
| Kingston | 16.2 | 28.9 | 34.9 | 8.9 | 12.5 | 101.4 |
| TOTAL | 58.1 | 62.9 | 56.8 | 21.9 | 13.4 | 213.1 |
Company Description
Grupo Aeroportuario del PacÃfico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexicoâs Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali and Los Mochis. In February 2006, GAPâs shares were listed on the New York Stock Exchange under the ticker symbol âPACâ and on the Mexican Stock Exchange under the ticker symbol âGAPâ. In April 2015, GAP acquired 100% of Desarrollo de Concesiones Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the operation of the Norman Manley International Airport in Kingston, Jamaica and took control of the operation in October 2019.
This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on managementâs current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words âanticipatesâ, âbelievesâ, âestimatesâ, âexpectsâ, âplansâ and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.
In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and article 42 of the âLey del Mercado de Valoresâ, GAP has implemented a âwhistleblowerâ program, which allows complainants to anonymously and confidentially report suspected activities that may involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party that is in charge of collecting these complaints, is 01 800 563 00 47. The web site is www.lineadedenuncia.com/gap. GAPâs Audit Committee will be notified of all complaints for immediate investigation.
| IR Contacts: | Â |
| Saúl Villarreal, Chief Financial and Administrative Officer | svillarreal@aeropuertosgap.com.mx |
| Alejandra Soto, IR and Financial Planning Manager | asoto@aeropuertosgap.com.mx |
| Gisela Murillo, Investor Relations | gmurillo@aeropuertosgap.com.mx / +523338801100 ext.20294 |
| Maria Barona, i-advize Corporate Communications | mbarona@i-advize.com |
Giga-tronics Incorporated Announces Completion of Previously Announced Reverse Split of Common Stock
Company undertakes reverse split with the intent to uplist to a national securities exchange
DUBLIN, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- (OTCQB: GIGA) Giga-tronics Incorporated (the âCompanyâ) announced today that its previously announced 1-for-15 reverse split of its common stock would become effective as of December 12, 2019. Beginning on December 13, 2019, the Companyâs common stock will trade on the OTC market on a split-adjusted basis.
As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced by the ratio of 1-for-15 to 2,476,982.  The number of authorized shares of the Companyâs common stock has been reduced in the same proportion to 13,333,333 shares of common stock. The reverse stock split impacts all holders of the Companyâs common stock uniformly and will not impact any shareholderâs percentage ownership interest in the Company; however, no fractional shares will be issued in connection with the reverse stock split, and cash will be paid in lieu of any fractional shares. The reverse stock split also reduces the number of shares of common stock issuable upon the conversion of the Companyâs outstanding shares of preferred stock and the exercise of its outstanding stock options and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the conversion and exercise prices of such preferred stock, stock options and warrants.
The Companyâs common stock will continue to trade on the OTC under the symbol âGIGAâ, although the letter âDâ will be added to the end of the trading symbol for approximately 20 trading days after the effective time of the split to designate that it is trading on a post-split basis. The new CUSIP number for the common stock following the reverse stock split is 37517504.
Registered shareholders holding their shares of common stock in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the reverse stock split. For those shareholders holding physical stock certificates, the Companyâs transfer agent, American Stock Transfer & Trust Company, LLC, will send instructions for exchanging those certificates for new certificates representing the post-split number of shares. The transfer agentâs phone number is AST can be reached at (877) 248-6417.
About Giga-tronics Incorporated
Giga-tronics produces sophisticated test and measurement equipment primarily used in electronic warfare test and emulation applications as well as YIG (Yttrium, Iron, Garnet) tuned oscillators, RADAR filters, and microwave synthesizers for use in military defense applications.
Forward Looking Statements
This press release contains forward-looking statements, including statements about the possible listing of a the Companyâs common stock on a national securities exchange, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, the risk that the Company and its common stock may be unable to satisfy the listing requirements of a national securities exchange notwithstanding the reverse split and those other risk factors contained in its filings made with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
| Company Contact:Â Lutz Henckels |
| Executive Vice President & CFO |
| (925) 328-4650 ext. 4698Â Agency Contact John Nesbett/Jennifer Belodeau IMS Investor Relations (203) 972-9200 jnesbett@institutionalms.com |
Â
CAPREIT Expands Presence in Calgary Market
TORONTO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (âCAPREITâ) (TSX:CAR.UN) announced today that it has completed the acquisition of The Carrington, a 79-suite apartment property located in the Beltline district of downtown Calgary, Alberta. Occupancy for the property currently stands at 100%. CAPREIT paid approximately $19.5 million for the property, funded by its Acquisition and Operating credit facility.
The Carrington offers larger-than-average suites, parking stalls, and storage units, providing an ideal space for families and upscale residents in the prestigious Beltline neighborhood. This attractive property, built in 1999, features average suites at 970 square feet. It contains a mix of spacious one-, two- and three-bedroom suites, all including balconies, kitchen appliances and in-suite laundry. The building is close to Calgaryâs downtown core, an elementary school, numerous retail amenities, and is in proximity to public transportation to the cityâs Light Rail Transit (LRT) system.
âWe are pleased to be adding this high-quality property to our portfolio in a well-located area of downtown Calgary,â commented Mark Kenney, President and CEO.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
ABOUT CAPREIT
Canadian Apartment Properties REIT (âCAPREITâ) is one of Canadaâs largest real estate investment trusts managing approximately 64,000 residential rental apartment and townhouse suites and manufactured home community sites in major urban centres across Canada, the Netherlands, and Ireland. For more information about CAPREIT, its business and its investment highlights, please refer to our website at www.caprent.com or www.capreit.net and our public disclosure at www.sedar.com.
CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS
All statements in this press release that do not relate to historical facts constitute forward-looking statements. These statements represent CAPREIT's intentions, plans, expectations and beliefs and are subject to certain risks and uncertainties that could result in actual results differing materially from these forward-looking statements. These risks and uncertainties are more fully described in regulatory filings that can be obtained on SEDAR at www.sedar.com.
For more information, please contact:
| CAPREIT Mr. Michael Stein Chairman (416) 861-5788 | CAPREIT Mr. Mark Kenney President & CEO (416) 861-9404 | CAPREIT Mr. Scott Cryer Chief Financial Officer (416) 861-5771 |
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
-- VYONDYS 53 is Sareptaâs second RNA exon-skipping treatment for DMD approved in the U.S. --
-- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately --
-- Information for patients and clinicians is available at www.SareptAssist.com --Â
CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYONDYS 53⢠(golodirsen). VYONDYS 53 is an antisense oligonucleotide from Sareptaâs phosphorodiamidate morpholino oligomer (PMO) platform, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. This indication is based on a statistically significant increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53, which is reasonably likely to predict clinical benefit for those patients who are exon 53 amenable. Consistent with the accelerated approval pathway, the continued approval of VYONDYS 53 may be contingent on confirmation of a clinical benefit in this post-marketing confirmatory trial.
Sareptaâs placebo-controlled, post-marketing confirmatory trial to support the VYONDYS 53 accelerated approval â titled ESSENCE â is currently enrolling and expected to conclude by 2024.Â
Hypersensitivity reactions, including rash, pyrexia (fever), pruritis, urticaria (hives), dermatitis, and skin exfoliation have occurred in patients who were treated with VYONDYS 53. Renal toxicity was observed in animal studies. Although not observed in the clinical studies with VYONDYS 53, renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. The most common adverse reactions that occurred in at least 20% of VYONDYS 53-treated patients and more frequently than in placebo-treated patients were headache (41%), pyrexia (41%), fall (29%), abdominal pain (27%), nasopharyngitis (27%), cough (27%), vomiting (27%), and nausea (20%).Â
Following a New Drug Application (NDA) submission to and review by the Division of Neurology Products (the Review Division) for VYONDYS 53, which the Review Division recommended for approval, the Office of Drug Evaluation 1 issued a complete response letter (CRL) in August of 2019. Thereafter, Sarepta made a formal dispute resolution request as outlined in relevant FDA Guidance. With the support of the Review Division, the matters raised in the CRL were rapidly evaluated and resolved by Dr. Peter Stein, Director of the Office of New Drugs (OND). OND granted the Companyâs appeal and Sarepta re-submitted its NDA to the Review Division, which worked expeditiously to review and approve VYONDYS 53.
âToday is monumental for Sarepta and, more importantly, for the DMD community,â said Doug Ingram, president and chief executive officer, Sarepta. âVYONDYS 53, our second approved exon-skipping RNA therapy for DMD, may treat up to 8% of the DMD community, representing those patients who have a confirmed exon 53 amenable mutation. Along with EXONDYS 51® (eteplirsen), we now offer treatment options for approximately 20% of those with DMD in the U.S.â
Ingram continued, âIn the span of four months, we commenced and completed the formal dispute resolution process culminating in the grant of our appeal, resubmitted our NDA and obtained an approval â a great benefit to DMD patients awaiting treatment. This unprecedented timing could not have been achieved without the commitment of the Review Division under the leadership of Dr. Billy Dunn, and the Office of New Drugs, which expeditiously heard and granted our appeal. Along with the DMD community, we owe our gratitude to both the Review Division and the OND for their objective, evidence-based approach to this review, for their fairness, and for the sense of urgency with which they addressed and resolved the CRL and granted this approval.â
âWith the approval of VYONDYS 53, up to another 8% of Duchenne families will have a therapy to treat this devastating disease,â said Pat Furlong, founding president and chief executive officer, Parent Project Muscular Dystrophy (PPMD). âFor 25 years, PPMD has been working with researchers, clinicians, industry, and the Duchenne community to find treatments for all people living with Duchenne. And while we need to ensure that these approved therapies are accessible for patients, today we celebrate this approval and thank Sarepta for their continued leadership in the fight to end Duchenne.â
VYONDYS 53 is priced at parity to EXONDYS 51, the price of which has not increased since its launch in 2016. Patients and physicians can access more information at www.SareptAssist.com or by calling 1-888-727-3782.
About VYONDYS 53
VYONDYS 53 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VYONDYS 53 uses Sareptaâs proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion, or âskipping,â of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
VYONDYS 53 is approved under accelerated review based on an increase in dystrophin production in skeletal muscle of patients amenable to exon 53 skipping. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
VYONDYS 53 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information for VYONDYS 53
Hypersensitivity reactions, including rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the VYONDYS 53 therapy.
Renal toxicity was observed in animals who received golodirsen. Although renal toxicity was not observed in the clinical studies with VYONDYS 53, renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Renal function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of renal function in DMD patients. Measurement of glomerular filtration rate (GFR) by 24-hour urine collection prior to initiation of therapy is recommended. Monthly monitoring for proteinuria by dipstick urinalysis and monitoring of serum cystatin C every three months is recommended. In the case of a confirmed dipstick proteinuria of 2+ or greater or elevated serum cystatin C, a 24-hour urine collection to quantify proteinuria and assess GFR should be performed.
Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).
Other adverse reactions that occurred at a frequency greater than 5%Â of VYONDYS 53-treated patients and at a greater frequency than placebo were administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.
For further information, please see the full Prescribing Information.
About EXONDYS 51
EXONDYS 51 uses Sareptaâs proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. EXONDYS 51 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
Important Safety Information About EXONDYS 51
Hypersensitivity reactions, including rash and urticaria, pyrexia, flushing, cough, dyspnea, bronchospasm, and hypotension, have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.
Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.
In the 88 patients who received â¥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in â¥10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.
For further information, please see the full Prescribing Information.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Companyâs programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit www.sarepta.com.
Forward-Looking Statement
This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the immediate commencement of commercial distribution of VYONDYS 53 in the U.S.; VYONDYS 53âs continued approval for its indication potentially being contingent upon verification of a clinical benefit in confirmatory trials; the potential benefits and risks of VYONDYS 53; VYONDYS 53âs potential to treat up to another 8% of those living with DMD; the potential of EXONDYS 51 and VYONDYS 53 to treat up to 20% of those with DMD in the U.S.; exon skippingâs intention to allow for production of an internally truncated dystrophin protein; and our mission to profoundly improve and extend the lives of patients with rare genetic-based diseases.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptaâs control. Known risk factors include, among others: the planned commercial launch in the U.S. for VYONDYS 53 may not be successful for various reasons including the actual market size and drug supply needed may not be consistent with the companyâs expectations and its executed commercial readiness plans, the degree to which VYONDYS 53 is accepted by patients and prescribed by physicians, manufacturing limitations that may not be anticipated or resolved for in a timely manner or at all, the efficiency of our manufacturing, sales, distribution and specialty pharmacy network in getting VYONDYS 53 to the market and future economic, competitive, reimbursement and regulatory conditions that could negatively impact the commercial launch of VYONDYS 53; we may not be able to comply with all FDA post-approval commitments and requirements with respect to EXONDYS 51 and VYONDYS 53 in a timely manner or at all; we may not be able to complete clinical trials required by the FDA or other regulatory authorities for approval of our product candidates; the results of our ongoing research and development efforts and clinical trials for our products and product candidates may not be positive or consistent with prior results or demonstrate a safe treatment benefit or support an NDA or a BLA filing, positive advisory committee recommendation or marketing approval by the FDA or other regulatory authority; we may not be able to execute on our business plans including meeting our expected or planned regulatory milestones and timelines, clinical development plans and bringing our product candidates to market, including the commercialization of VYONDYS 53, for various reasons, including factors outside of our control, such as possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner or at all, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product and product candidates; and those risks identified under the heading âRisk Factorsâ in Sareptaâs most recent Annual Report on Form 10-K for the year ended December 31, 2018, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Companyâs business, results of operations and the trading price of Sareptaâs common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2018 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the SEC as well as other SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.Â
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Tourism Authority of Thailand joins hands with Thai private sector to organise biggest national new year countdown fireworks along river at ICONSIAM
'Amazing Thailand Countdown 2020' will be largest ever
"By organizing such an extraordinary fireworks display we aim to promote the Chao Phraya River as an exciting new destination for international visitors"
Mr. Yuthasak Supasorn, Governor, Tourism Authority of Thailand
BANGKOK, Dec, 13, 2019 /PRNewswire/ -- The Tourism Authority of Thailand (TAT) in partnership with river-related business associations, ICONSIAM and True Corporation are organizing the largest ever Thailand national new year countdown event along the Chao Phraya River at ICONSIAM to herald in the new year on the evening of 31stDecember 2019.
Called 'Amazing Thailand Countdown 2020', the national countdown event includes a spectacular fireworks display along 1.4 kilometres of the Chao Phraya River.
Mr. Yuthasak Supasorn, Governor of the Tourism Authority of Thailand, said, "By organizing such an extraordinary fireworks display, we aim to promote the Chao Phraya River as a thrilling new destination for international visitors through the excitement it will create around the river as well as by the worldwide news coverage it will attract on global media channels."
He said that the TAT is also organizing multiple other events throughout Thailand to support the travel sector and its contribution to the national and regional economies in Ratchaburi, Chiang Rai, Phatthalung, Kalasin, Sa Kaeo and Lopburi.
Mr. Supoj Chaiwatsirikul, Managing Director of ICONSIAM Co., Ltd., said, "ICONSIAM is proud to support and host this magnificent, riverside event that helps to re-ignite the glory of the river. Its unprecedented scale, made possible through the collaboration of multiple partners, will ensure that the fireworks show will be visible, live, to more than a million people within a radius of two kilometres."
He said, "There are many locations from which to observe the display in addition to the ICONSIAM River Park, and include the 7th floor of ICONSIAM, as well as the venues of the national countdown partners, such as Charoenkrung Creative District, Lhong 1919, Asiatique The Riverfront, The Mandarin Oriental Bangkok, The Peninsula Bangkok, The Royal Orchid Sheraton, The Millennium Hilton Bangkok, and the Shangri-La Bangkok."
Mr. Chaiwatsirikul added that the partners are all also organizing various celebratory activities and shows at their own premises, which, together, will make the Chao Phraya River the most exciting place to be during the new year countdown.
Other locations offering good views of the fireworks display are Chaloem Phrakiat Park, Sathorn Pier, Wat Suwan Pier, The Royal Thai Marine Sub-Division 2, Communications Authority of Thailand building in Bangrak, Klongsan Pier, the Holy Rosary Church, and Sampeng car park.
According to Mr. Chaiwatsirikul, the fireworks use Japanese technology that utilizes sticky rice in its manufacture and which makes them more sustainable as well as minimizes their impact on the environment.
He said, "We invite visitors from around the world and hope to welcome them to participate in the many exciting activities that we are organizing as well as to view the unforgettably amazing fireworks show."
This year's edition of the fireworks display is called the 'Seven Wonders of Blessings' and is comprised of seven 'acts' that have auspicious meanings, embracing Thailand's rich history, its prosperity, religion, monarchy and agricultural bountifulness.
Photo - https://photos.prnasia.com/prnh/20191213/2670088-1
SOURCE ICONSIAM
OHA Investment Corporation Announces Stockholder Approval of Proposed Merger With Portman Ridge Finance Corporation
NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- OHA Investment Corporation (Nasdaq: OHAI) (the âCompanyâ or âOHAIâ) announced today that it obtained stockholder approval for its proposed merger (the âMergerâ) with Portman Ridge Finance Corporation (Nasdaq: PTMN) (âPTMNâ) at a special meeting of the Companyâs stockholders held on December 12, 2019. The Merger is currently expected to close on or around December 18, 2019, subject to satisfaction of customary closing conditions.
The voting results to approve the Merger were as follows:
| Â | Votes For | Â | Votes Against | Â | Abstentions | Â |
| Â | 14,262,989 | Â | 321,520 | Â | 93,592 | Â |
Over 97% of the OHAI stockholders who voted at the meeting voted in favor of the proposal related to effecting the proposed merger.
âWe are pleased that OHAI stockholders overwhelmingly approved the Merger with Portman Ridge Finance Corporation,â said Steven Wayne, OHAIâs President and Chief Executive Officer, âWe believe our stockholders will continue to realize significant identifiable value through their continued ownership of PTMN common stock and partnership with the credit team at BC Partners after the closing of the Merger.â
About OHA Investment Corporation
OHA Investment Corporation (NASDAQ: OHAI) is a specialty finance company designed to provide its investors with current income and capital appreciation. OHAI focuses primarily on providing creative direct lending solutions to middle market private companies across industry sectors. OHAI is externally managed by Oak Hill Advisors, L.P., a leading independent investment firm (www.oakhilladvisors.com). OHAIâs filings with the Securities and Exchange Commission (âSECâ), earnings releases, press releases and other financial, operational and governance information are available on OHAIâs website at http://ir.ohainvestmentcorporation.com/home.
Forward-Looking Statements
This press release may contain forward-looking statements. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those expressed or implied in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. OHAI undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
CONTACTS:
Steven T. Wayne â President and Chief Executive Officer
Cory E. Gilbert â Chief Financial Officer
Kahyeong Lee â Chief Compliance Officer
OHAICInvestorRelations@oakhilladvisors.com
For media inquiries, contact Kekst and Company, (212) 521-4800
Jeremy Fielding â jeremy.fielding@kekstcnc.com
Clinical Data from Reprieve Cardiovascular's Successful First-in-Human Therapy for Acute Heart Failure Presented
MILFORD, Mass., Dec. 13, 2019 /PRNewswire/ -- Reprieve Cardiovascular®, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced the results of the first-in-human clinical trial with the company's second generation device, the Personalized Volume Management System (PVM). The study demonstrated that the fully automated fluid management system resulted in safe, effective, efficient and long-lasting decongestion for patients with Acute Heart Failure. The results were presented today at the Device Therapies in Heart Failure (D-HF 2019) meeting in Paris, France.
The 15-patient clinical trial was designed to determine whether the Reprieve Personalized Volume Management System could more efficiently and safely achieve reductions in net volume and AHF symptoms.
Data highlights:
- Average net fluid removal: -5.9 L/therapy, normalized to -4.5 L/24 hr.
- Average weight loss after mean treatment duration of 31 hrs: -6.8 kg.
- Average weight loss of -5.7 kg (from baseline) was maintained at 30-day follow-up in 12 patients who completed the 30-day follow-up.
- Average sodium removal was -798 mmol per therapy, normalized to -611 mmol/24 hr.
- No re-hospitalization of patients who have completed the 30-day follow-up.
- No significant adverse events were reported.
Device benefits for AHF treatment:
- The Reprieve Personalized Volume Management System, designed to speed fluid removal and symptom relief with the lowest effective diuretic dose for each patient, automatically tailors diuretic dosing.
- "Set and forget" convenience.
- Provides personalized fluid management to prevent hypotension and the activation of salt- and water-retaining renal mechanisms.
"We're very encouraged by these first in man results with our new Personalized Volume Management System," said Reprieve Cardiovascular Chief Medical Officer Howard Levin, M.D. "The trends in all of the core metrics that matter to heart failure physicians and patients, including length of stay, weight reduction, and re-hospitalization point in a positive direction. We look forward to continuing this clinical work to support the adoption of PVM as a standard of care for improved treatment of patients with ADHF."
About ADHF
ADHF is a sudden onset of heart failure symptoms, which typically include difficulty breathing (dyspnea), swelling in the extremities, and fatigue. The signs and symptoms of fluid overload are responsible for 90% of heart failure hospital admissions. Current treatment for ADHF includes diuretic therapy that aims to restore healthy fluid levels in the kidneys and throughout the body. Standard diuretic therapy, however, can be unpredictable and lose effectiveness as a patient's condition deteriorates. In some patients, diuretics can trigger a condition called "diuretic resistance," which blunts the function of diuretics and can exacerbate the severity of fluid overload, potentially resulting in acute kidney injury.
About Reprieve Cardiovascular's Personalized Volume Management System
Reprieve Cardiovascular's Personalized Volume Management System, a second-generation automated fluid management system, is designed to better manage diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF) and may relieve a number of symptoms related to this condition. The therapy is designed to enable more precise, predictable and efficient management of a patient's fluid levels, guarding against dangerous fluid imbalances and enabling better control over diuretic therapy. Potential benefits include speeding decongestion while protecting core organ function, reducing symptoms of congestive heart failure such as shortness of breath, ascites, and swelling, reduced time in hospital, reduced readmission rates, and a better quality of life for patients.
About Reprieve Cardiovascular
Reprieve Cardiovascular is a pioneering medical device company focused on automated fluid management technologies for acute heart failure treatment. The company's Reprieve technology is being investigated as an innovative fluid management treatment that provides clinicians with the ability to precisely control a patient's fluid volume and may enable improved cardiac care with safe, effective decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. For more information, visit www.reprievecardio.com and follow us on Twitter at @ReprieveCardio.
Please visit us at our D-HF 2019 booth.
View original content:http://www.prnewswire.com/news-releases/clinical-data-from-reprieve-cardiovasculars-successful-first-in-human-therapy-for-acute-heart-failure-presented-300974359.html
SOURCE Reprieve Cardiovascular
Rapid Diagnostics Expert Joins Verifi H2O Advisory Board
MONTCLAIR, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Verifi H2O, an innovative water-monitoring platform delivering real-time water quality intelligence, has announced the addition of Dr. James Stave to its advisory board.
Dr. Stave is a globally recognized rapid diagnostics expert with over 35 years of experience in the research, design, and development of rapid commercial tests for detection of contaminants, especially microbes in water matrices. He is also the inventor of patents involving novel reagents, methods, and devices including microfluidics to improve sensitivity and specificity in test methods. His roles as scientist, Vice President of R&D, and Chief Science Officer have resulted in the successful development and commercialization of over 50 rapid diagnostic products.
âAccelerating the time to detection of water pathogens and other water contaminants is a challenging and important endeavor, and I am excited to advise and assist Verifi H2O in achieving their goals and objectives. I look forward to our successful relationship developing and delivering commercially superior products to benefit the global water community.â said Dr. James Stave.
âWe are humbled and honored to have Dr. Stave join our advisory board,â said Jim Poder, Verifi H2Oâs President and COO. âJim has a wealth of expertise and experience with rapid diagnostic systems. He has a passion for making the most of R&D to deliver commercially viable products and we will benefit tremendously from having him on our advisory board.â
Verifi H2Oâs initial water quality surveillance systems will be available for commercial use in premise water systems for hospitals, hotels and facilities with cooling towers. Future systems will be designed and manufactured for residential applications.
About Verifi H2O
Verifi H2O is an innovative water-monitoring platform delivering real-time water quality intelligence. Verifiâs water quality surveillance systems are based on proprietary, advanced material technologies that enable the rapid detection of pathogens, contaminants, and chemicals of concern. Our systems provide customers with reliable information to make time sensitive decisions. Learn more at www.verifiwater.com.
OMRON and Square Enix Launch Joint Research on "AI That Helps Motivate Humans"
KYOTO, Japan, Dec. 13, 2019 /PRNewswire/ -- OMRON Corporation of Kyoto and Square Enix Co., Ltd. (hereinafter "Square Enix") of Tokyo announced on December 13 the commencement of joint research on "artificial intelligence (AI) that helps motivate humans for FORPHEUS, an innovative table tennis robot tutor that harnesses OMRON's state-of-the-art technology. Through this joint research, the two companies aim to develop an AI algorithm that generates motivational feedback from vital data and other kinds of information, thereby establishing technology that brings out the ability to stimulate dramatic human growth.
Based on the philosophy of founder Kazuma Tateisi, "To the machine, the work of the machine; to man, the thrill of further creation," OMRON aims to shape a future that achieves "harmony between humans and machines," with the latter bringing out the abilities and creativity of the former through the core technology "Sensing & Control + Think." In 2013, the table tennis robot "Forpheus" was developed in order to introduce "harmony between humans and machines" by the core technology "Sensing & Control + Think" in an easy-to-understand manner. Since then, OMRON has evolved its core technology every year to bring out human abilities. Featuring cutting-edge AI, robotics, and sensing & control technologies, the latest 5th-generation FORPHEUS possesses playing skills high enough to maintain a rally with professional players. The robot's excellent coaching skills promote the growth of human players by optimizing returns and providing players with personalized tips based on a thorough understanding of each individual person.
Under the framework of this joint research, the two companies aim to develop AI that can realize personalized coaching to enhance each player's motivation to play better by combining OMRON's proprietary "sensing technology for reading human emotions and ability" and Square Enix's "AI technology (Meta-AI*) for differentiating how a game unfolds for each player to stimulate an emotional response in them," which the company has fostered through the development of electronic games. As humans communicate with machines equipped with this AI while they play table tennis together, it is hoped that a new relationship between humans and machines -- machines drawing the best performance out of humans -- will be made a reality.
The Advanced Technology Division (ATD) at Square Enix has been leading development of Meta-AI technologies, a new mechanic that can automatically learn from a user's emotions and then produce unique content based on the data. In the near future, it is expected that a digital game will be playable not only on a display screen but also in real space. Square Enix's Meta-AI will have an important role in realizing the potential of real space play in the future and the company's partnership with the FORPHEUS project will allow Square Enix to advance its technology and contribute to this real-world opportunity.
Meanwhile, OMRON plans to apply the fruits of this joint technology development to focus on business domains such as factory automation (FA), healthcare and social solutions. One industrial sector in which such technologies may be applied is factory automation, where machines can better motivate operators by offering appropriate support in a way that matches operators' skill levels. OMRON believes that this joint research of FORPHEUS will advance its drive to solve social issues to achieve "harmony between humans and machines."
OMRON will exhibit its latest generation of FORPHEUS at the Consumer Electronics Show (CES) (R) 2020, which will be held in Las Vegas, Nevada, the U.S., on January 7-10, 2020.
*In games, Meta-AI observes the characters, environment and players all together over time, and then uses the information to adapt the general strategies for enemies, non-player characters, terrain, weather and more in the game.
About this joint research
- Duration: From December 2019 to March 2020
- Objective: Development of an algorithm for motivation-controlling AI for use in a table tennis robot tutor
- Division of roles:
OMRON: Development of a concept and architecture for the table tennis robot, verification of effects, and study of algorithm improvement techniques Square Enix: Development of a concept, designing of architecture for the motivation-controlling AI, setting of evaluation indicators, provision of advice/support for development, and study of algorithm improvement techniques
About FORPHEUS
FORPHEUS embodies the concept of "harmony between humans and machines," that is, machines bringing out the abilities and creativity of humans using OMRON's core technology of "Sensing & Control + Think." The development of this table tennis tutor robot began in 2013, and its 5th-generation model attracted significant attention at CES 2019. It is made up of robots, sensors, controllers and other products that OMRON's Industrial Automation Business distributes, and technologies developed for FORPHEUS are put to commercial applications.
Photo: 5th-generation FORPHEUS
https://kyodonewsprwire.jp/prwfile/release/M102197/201912104564/_prw_PI1lg_B8Sr5d30.jpg
In this joint research, FabCafe operated by Loftwork Inc. cooperates in project management.
About OMRON Corporation
OMRON Corporation is a global leader in the field of automation based on its core technology of "Sensing & Control + Think." OMRON's business fields cover a broad spectrum, ranging from industrial automation and electronic components to social infrastructure systems, healthcare, and environmental solutions. Established in 1933, OMRON has about 35,000 employees worldwide, working to provide products and services in around 120 countries and regions. For more information, visit OMRON's website: https://www.omron.com/
About Square Enix Co., Ltd.
Square Enix Co., Ltd. develops, publishes, distributes and licenses entertainment content branded SQUARE ENIX(R), EIDOS(R) and TAITO(R) around the world. The Square Enix group of companies includes a global network of leading development studios and boasts a valuable portfolio of intellectual property, including: FINAL FANTASY(R), which has sold over 147 million units worldwide; and DRAGON QUEST(R), which has sold over 78 million units worldwide; TOMB RAIDER(R), which has sold over 74 million units worldwide; and the legendary SPACE INVADERS(R). Square Enix Co., Ltd. is a Japan-based, wholly owned subsidiary of Square Enix Holdings Co., Ltd. More information on Square Enix Co., Ltd. can be found at https://www.jp.square-enix.com/
About Advanced Technology Division at Square Enix
The Advanced Technology Division (ATD) at Square Enix conducts applied research and develops core technologies covering all aspects of games. One of ATD's goals is to help create new markets by using advanced game technologies. In particular, ATD hopes to see its proven game AI technology contribute to society and people's lives.
About FabCafe
Logo: https://kyodonewsprwire.jp/img/201912104564-O2-9E8NA72j
The term FAB incorporates the meanings of both FABulous and FABrication, free from the constraints of mass production and market theory. FabCafe shares the FAB spirit in a fun and user-friendly manner, while providing an open platform to support individuals in their creative efforts to make new things. FabCafe believes that its community will bring innovation to the future of making. (https://fabcafe.com/)
View original content:http://www.prnewswire.com/news-releases/omron-and-square-enix-launch-joint-research-on-ai-that-helps-motivate-humans-300974469.html
SOURCE OMRON Corporation
First Federal lawsuit was filed linked to the most recent Romaine lettuce E. coli outbreak
Seattle, Wa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- A lawsuit was filed on behalf of Cindy Day against Aldiâs Inc., in Federal District Court in Iowa. Ms. Day is represented by Marler Clark, the food safety law firm, and Wandro and Associates, a local Des Moines firm. Case 4:19-cv-00399-RP-CFB.
On or about November 2, 2019, Ms. Day purchased an Asian Chopped Salad mix from Aldi located at 8400 Douglas Ave, Urbandale, Iowa. This product contains romaine lettuce. On Thursday, November 7, 2019, Ms. Day began to experience diarrhea. Her condition continued to deteriorate to include vomiting and her diarrhea became bloody on Saturday, November 9, 2019. Ms. Day sought medical care at a local clinic, where she was given anti-nausea medication. A stool sample provided to the clinic tested positive for E. coli O157:H7. Polk County Health Department informed her that her strain of E. coli O157:H7 is a genetic to other outbreak cases.
"We are filing lawsuits, not only to seek compensation for our clients, but to help determine the source of the contamination that has sickened so many," said Marler Clark managing partner, Bill Marler. âThrough the litigation process, we will show how this contamination occurred and who was involved. It is only when all this information is gathered and transparently shared that we can learn how to prevent the next E. coli O157:H7 outbreak," added Marler.
 As of December 2, 2019, 102 people infected with E. coli O157:H7 have been reported from 23 states. There have been over 50 hospitalizations, with at least 10 with acute kidney failure. Illnesses started on dates ranging from September 24 to November 18. As of December 6, the Public Health Agency of Canada has reported two illnesses related to the U.S. outbreak. Based on available traceback data, the FDA requested that industry voluntarily withdraw romaine lettuce grown in Salinas, California from the market and is requesting that the industry withhold distribution of romaine for the remainder of the growing season in Salinas. Consumers are still advised to not eat, and retailers and food service establishments to not sell or serve, any romaine lettuce harvested from the Salinas growing region.
 E. coli O157:H7 outbreaks associated with lettuce, specifically the âpre-washedâ and âready-to-eatâ varieties, are by no means a new phenomenon. In fact, the frequency with which this countryâs fresh produce consuming public has been hit by outbreaks of pathogenic bacteria is astonishing. Here is just a sample of E. coli outbreaks based on information gathered by the Center for Science in the Public Interest, Kansas State University, and the Centers for Disease Control and Prevention:
Â
| Date | Vehicle | Etiology | Confirmed Cases | States/Provinces |
| July 1995 | Lettuce (leafy green; red; romaine) | E. coli O157:H7 | 74 | 1:MT |
| Sept. 1995 | Lettuce (romaine) | E. coli O157:H7 | 20 | 1:ID |
| Sept. 1995 | Lettuce (iceberg) | E. coli O157:H7 | 30 | 1:ME |
| Oct. 1995 | Lettuce (iceberg; unconfirmed) | E. coli O157:H7 | 11 | 1:OH |
| May-June 1996 | Lettuce (mesclun; red leaf) | E. coli O157:H7 | 61 | 3:CT, IL, NY |
| May 1998 | Salad | E. coli O157:H7 | 2 | 1:CA |
| Feb.-Mar. 1999 | Lettuce (iceberg) | E. coli O157:H7 | 72 | 1:NE |
| Oct. 1999 | Salad | E. coli O157:H7 | 92 | 3:OR, PA, OH |
| Oct. 2000 | Lettuce | E. coli O157:H7 | 6 | 1:IN |
| Nov. 2001 | Lettuce | E. coli O157:H7 | 20 | 1:TX |
| July-Aug. 2002 | Lettuce (romaine) | E. coli O157:H7 | 29 | 2:WA, ID |
| Nov. 2002 | Lettuce | E. coli O157:H7 | 13 | 1:Il |
| Dec. 2002 | Lettuce | E. coli O157:H7 | 3 | 1:MN |
| Oct. 2003-May 2004 | Lettuce (mixed salad) | E. coli O157:H7 | 57 | 1:CA |
| Apr. 2004 | Spinach | E. coli O157:H7 | 16 | 1:CA |
| Nov. 2004 | Lettuce | E. coli O157:H7 | 6 | 1:NJ |
| Sept. 2005 | Lettuce (romaine) | E. coli O157:H7 | 32 | 3:MN, WI, OR |
| Sept. 2006 | Spinach (baby) | E. coli O157:H7 and other serotypes | 205 | Multistate and Canada |
| Nov./Dec. 2006 | Lettuce | E. coli O157:H7 | 71 | 4:NY, NJ, PA, DE |
| Nov./Dec. 2006 | Lettuce | E. coli O157:H7 | 81 | 3:IA, MN, WI |
| July 2007 | Lettuce | E. coli O157:H7 | 26 | 1:AL |
| May 2008 | Romaine | E. coli O157:H7 | 9 | 1:WA |
| Oct. 2008 | Lettuce | E. coli O157:H7 | 59 | Multistate and Canada |
| Nov. 2008 | Lettuce | E. coli O157:H7 | 130 | Canada |
| Sept. 2009 | Lettuce: Romaine or Iceberg | E. coli O157:H7 | 29 | Multistate |
| Sept. 2009 | Lettuce | E. coli O157:H7 | 10 | Multistate |
| April 2010 | Romaine | E. coli O145 | 33 | 5:MI, NY, OH, PA, TN |
| Oct. 2011 | Romaine | E. coli O157:H7 | 60 | Multistate |
| April 2012 | Romaine | E. coli O157:H7 | 28 | 1:CA Canada |
| June 2012 | Romaine | E. coli O157:H7 | 52 | Multistate |
| Sept. 2012 | Romaine | E. coli O157:H7 | 9 | 1:PA |
| Oct. 2012 | Spinach and Spring Mix Blend | E. coli O157:H7 | 33 | Multistate |
| Apr. 2013 | Leafy Greens | E. coli O157:H7 | 14 | Multistate |
| Aug. 2013 | Leafy Greens | E. coli O157:H7 | 15 | 1:PA |
| Oct. 2013 | Ready-To-Eat Salads | E. coli O157:H7 | 33 | Multistate |
| Apr. 2014 | Romaine | E. coli O126 | 4 | 1:MN |
| Apr. 2015 | Leafy Greens | E. coli O145 | 7 | 3:MD, SC, VA |
| June 2016 | Mesclun Mix | E. coli O157:H7 | 11 | 3:IL, MI, WI |
| Nov. 2017 | Leafy Greens | E. coli O157:H7 | 67 | Multistate and Canada |
| Mar. 2018 | Romaine | E. coli O157:H7 | 219 | Multistate and Canada |
| Nov. 2018 | Romaine | E. coli O157:H7 | 88 | Multistate and Canada |
| Sept. 2019 | Romaine | E. coli O157:H7 | 23 | Multistate |
| Nov. 2019 | Romaine | E. coli O157:H7 | 104 | Multistate and Canada |
Â
Marler Clark, The Food Safety Law Firm, is the nationâs leading law firm representing victims of E. coli outbreaks and hemolytic uremic syndrome (HUS). The E. coli lawyers of Marler Clark have represented thousands of victims of E. coli and other foodborne illness infections and have recovered over $700 million for clients. Marler Clark is the only law firm in the nation with a practice focused exclusively on foodborne illness litigation. Our E. coli lawyers have litigated E. coli and HUS cases stemming from outbreaks traced to ground beef, raw milk, lettuce, spinach, sprouts, and other food products. The law firm has brought E. coli lawsuits against such companies as Jack in the Box, Dole, ConAgra, Cargill, and Jimmy Johnâs. We have proudly represented such victims as Brianne Kiner, Stephanie Smith and Linda Rivera.
- About E. coli â a complete online resource with information on symptoms and risks of E. coli infection
- Marler Clark E. coli Lawsuits and Litigation
- A downloadable Family Health Guide on E. coli (PDF)
- About Hemolytic Uremic Syndrome
SOURCE: Marler Clark, The Food Safety Law Firm â for further information, contact jdueck@marlerclark.com
Â
Attachment
